Canadian radioisotope firm Nordion reported an increase in revenue for the first quarter of its fiscal 2014 (end-January 31).
Revenue increased by 32% to $70.8 million for the first quarter of fiscal 2014, compared with $53.7 million for the same quarter of fiscal 2013.
First-quarter revenue for the company's Medical Isotopes segment more than doubled to $51.7 million, compared with $25.2 million in the first quarter of fiscal 2013. Reactor isotopes revenue rose by 98% to $40.4 million, due to additional orders of molybdenum-99 that resulted from supply interruptions affecting some of Nordion's competitors.
The company also had generally accepted accounting principles (GAAP) net income of $35.3 million in the first quarter, compared with a net loss of $269,000 in the first quarter of 2013.
